Simulations Plus Q2 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLP?
Source: seekingalpha
- Strong Performance: Simulations Plus reported a Q2 Non-GAAP EPS of $0.35, beating expectations by $0.05, which reflects the company's ongoing profitability enhancement and strengthens investor confidence.
- Revenue Growth: The company achieved revenue of $24.3 million, an 8.3% year-over-year increase, exceeding expectations by $2.64 million, indicating sustained competitiveness and demand for its products, likely driving future performance growth.
- Fiscal 2026 Guidance: Simulations Plus projects fiscal 2026 revenue between $79 million and $82 million, slightly below the consensus of $80.42 million, reflecting a cautious outlook on future market conditions while providing clear growth expectations for investors.
- Software Mix Optimization: The expected software revenue mix is projected to be between 57% and 62%, with adjusted EBITDA margins of 26% to 30%, indicating the company's strategic focus on optimizing its product mix and enhancing profitability, which may attract more investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 13.000
Low
19.00
Averages
19.00
High
19.00
Current: 13.000
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Simulations Plus Reports Q2 Adjusted EPS of $0.35, Beating IBES Estimate of $0.20
Economic Indicators: The latest simulations indicate a Q2 adjusted EPS of USD 0.35, which is higher than the previous estimate of USD 0.2.
Market Expectations: The revised EPS suggests a more optimistic outlook for the company's financial performance compared to earlier predictions.
See More
Simulations Plus Announces Financial Results for Second Quarter of Fiscal Year 2026
Financial Performance: Simulations Plus reported its financial results for the second quarter of fiscal 2026, highlighting key metrics and performance indicators.
Revenue Growth: The company experienced notable revenue growth compared to previous quarters, reflecting strong demand for its simulation software products.
See More
Simulations Plus to Announce Q2 Earnings on April 9th
- Earnings Announcement: Simulations Plus (SLP) is set to release its Q2 earnings report on April 9th after market close, with consensus EPS estimate at $0.30, reflecting a 3.2% year-over-year decline, and revenue estimate at $21.66 million, down 3.4% year-over-year.
- Performance Beat Record: Over the past two years, SLP has exceeded EPS estimates 63% of the time and revenue estimates 88% of the time, indicating the company's consistent financial performance and adaptability in the market.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced two upward revisions and three downward revisions, reflecting mixed market sentiment regarding the company's future performance.
- Long-term Revenue Guidance: Simulations Plus maintains its revenue guidance for 2026 between $79 million and $82 million, while accelerating AI integration, demonstrating the company's proactive strategy in responding to technological innovation and changing market demands.
See More
Simulations Plus Q2 Earnings Exceed Expectations
- Strong Performance: Simulations Plus reported a Q2 Non-GAAP EPS of $0.35, beating expectations by $0.05, which reflects the company's ongoing profitability enhancement and strengthens investor confidence.
- Revenue Growth: The company achieved revenue of $24.3 million, an 8.3% year-over-year increase, exceeding expectations by $2.64 million, indicating sustained competitiveness and demand for its products, likely driving future performance growth.
- Fiscal 2026 Guidance: Simulations Plus projects fiscal 2026 revenue between $79 million and $82 million, slightly below the consensus of $80.42 million, reflecting a cautious outlook on future market conditions while providing clear growth expectations for investors.
- Software Mix Optimization: The expected software revenue mix is projected to be between 57% and 62%, with adjusted EBITDA margins of 26% to 30%, indicating the company's strategic focus on optimizing its product mix and enhancing profitability, which may attract more investor interest.
See More
Major Earnings Reports Expected Thursday After the Bell
- Earnings Report Preview: After the market closes on Thursday, ClearSign Technologies Corporation (CLIR), Simulations Plus (SLP), and WD-40 Company (WDFC) are set to release their earnings reports, with market participants keenly awaiting their performance and future guidance.
- Market Reaction Expectations: Investors are particularly eager for these earnings, as the results could significantly influence stock price movements in the current economic climate, where performance is closely scrutinized.
- Industry Dynamics Analysis: ClearSign and Simulations Plus operate in the clean technology and simulation software sectors, respectively, while WD-40 holds a strong position in the consumer goods market; the earnings results will provide critical insights into market trends within these industries.
- Investor Strategy Adjustments: As the earnings release approaches, investors may adjust their portfolios based on anticipated results to navigate potential market volatility and capitalize on emerging opportunities.
See More
Simulations Plus Schedules Q2 2026 Earnings Call
- Earnings Report Announcement: Simulations Plus will release its Q2 fiscal 2026 financial results after market close on April 9, 2026, reflecting the company's ongoing innovation in drug development.
- Conference Call Timing: Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the financial results with investment professionals and current and prospective shareholders, enhancing transparency and communication.
- Participation Options: Investors can join the call by dialing 1-877-451-6152 for domestic or 201-389-0879 for international access, or by registering through a provided link to ensure timely information dissemination.
- Replay Availability: The webcast will be available for replay approximately one hour after the call on the Simulations Plus investor relations page, further improving interaction and information sharing between the company and its investors.
See More
Simulations Plus Reports Q2 Adjusted EPS of $0.35, Beating IBES Estimate of $0.20
Economic Indicators: The latest simulations indicate a Q2 adjusted EPS of USD 0.35, which is higher than the previous estimate of USD 0.2.
Market Expectations: The revised EPS suggests a more optimistic outlook for the company's financial performance compared to earlier predictions.
See More
Simulations Plus Announces Financial Results for Second Quarter of Fiscal Year 2026
Financial Performance: Simulations Plus reported its financial results for the second quarter of fiscal 2026, highlighting key metrics and performance indicators.
Revenue Growth: The company experienced notable revenue growth compared to previous quarters, reflecting strong demand for its simulation software products.
See More
Simulations Plus to Announce Q2 Earnings on April 9th
- Earnings Announcement: Simulations Plus (SLP) is set to release its Q2 earnings report on April 9th after market close, with consensus EPS estimate at $0.30, reflecting a 3.2% year-over-year decline, and revenue estimate at $21.66 million, down 3.4% year-over-year.
- Performance Beat Record: Over the past two years, SLP has exceeded EPS estimates 63% of the time and revenue estimates 88% of the time, indicating the company's consistent financial performance and adaptability in the market.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced two upward revisions and three downward revisions, reflecting mixed market sentiment regarding the company's future performance.
- Long-term Revenue Guidance: Simulations Plus maintains its revenue guidance for 2026 between $79 million and $82 million, while accelerating AI integration, demonstrating the company's proactive strategy in responding to technological innovation and changing market demands.
See More
Simulations Plus Q2 Earnings Exceed Expectations
- Strong Performance: Simulations Plus reported a Q2 Non-GAAP EPS of $0.35, beating expectations by $0.05, which reflects the company's ongoing profitability enhancement and strengthens investor confidence.
- Revenue Growth: The company achieved revenue of $24.3 million, an 8.3% year-over-year increase, exceeding expectations by $2.64 million, indicating sustained competitiveness and demand for its products, likely driving future performance growth.
- Fiscal 2026 Guidance: Simulations Plus projects fiscal 2026 revenue between $79 million and $82 million, slightly below the consensus of $80.42 million, reflecting a cautious outlook on future market conditions while providing clear growth expectations for investors.
- Software Mix Optimization: The expected software revenue mix is projected to be between 57% and 62%, with adjusted EBITDA margins of 26% to 30%, indicating the company's strategic focus on optimizing its product mix and enhancing profitability, which may attract more investor interest.
See More
Major Earnings Reports Expected Thursday After the Bell
- Earnings Report Preview: After the market closes on Thursday, ClearSign Technologies Corporation (CLIR), Simulations Plus (SLP), and WD-40 Company (WDFC) are set to release their earnings reports, with market participants keenly awaiting their performance and future guidance.
- Market Reaction Expectations: Investors are particularly eager for these earnings, as the results could significantly influence stock price movements in the current economic climate, where performance is closely scrutinized.
- Industry Dynamics Analysis: ClearSign and Simulations Plus operate in the clean technology and simulation software sectors, respectively, while WD-40 holds a strong position in the consumer goods market; the earnings results will provide critical insights into market trends within these industries.
- Investor Strategy Adjustments: As the earnings release approaches, investors may adjust their portfolios based on anticipated results to navigate potential market volatility and capitalize on emerging opportunities.
See More
Simulations Plus Schedules Q2 2026 Earnings Call
- Earnings Report Announcement: Simulations Plus will release its Q2 fiscal 2026 financial results after market close on April 9, 2026, reflecting the company's ongoing innovation in drug development.
- Conference Call Timing: Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the financial results with investment professionals and current and prospective shareholders, enhancing transparency and communication.
- Participation Options: Investors can join the call by dialing 1-877-451-6152 for domestic or 201-389-0879 for international access, or by registering through a provided link to ensure timely information dissemination.
- Replay Availability: The webcast will be available for replay approximately one hour after the call on the Simulations Plus investor relations page, further improving interaction and information sharing between the company and its investors.
See More
